A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome

Journal of Clinical Rheumatology

Volumn 5, Issue 2, 1999, Pages 56-59

  Himmel, Peter B ^a,b   Seligman, Trina M ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b NONE   (United States)

Author keywords

Chronic fatigue syndrome; Dehydroepiandrosterone (DHEA); Treatment

Indexed keywords

HYDROCORTISONE; PRASTERONE; PRASTERONE SULFATE;

ACNE; ADULT; ANXIETY; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DAILY LIFE ACTIVITY; DEPRESSION; DRUG EFFICACY; EMOTIONAL STRESS; FEMALE; GASTROINTESTINAL TOXICITY; HELPLESSNESS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MANIA; OBESITY; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PHYSICAL STRESS; PRIORITY JOURNAL; RASH; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0032942150     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199904000-00004     Document Type: Article

References (26)

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121:953-9.
2. Komaroff AL, Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis 1991;13 Suppl:S8-S11.
3. Farrar DJ, Locke SE, Kantrowitz FG. Chronic fatigue syndrome. 1: Etiology and pathogenesis. Behav Med 1995;21:5-16.
4. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, et al. Evidence for impaired activation of the hypothalamic-piruitary-adrenal axis in patients with chronic fatigue syndrome J Clin Endocrinol Metab 1991;73:1224-34.
5. Strickland P, Morriss R, Wearden A, Deakin B. A comparison of salivary Cortisol in chronic fatigue syndrome, community depression and healthy controls. J Affect Disord 1998;47:191-4.
6. McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M, et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998;280:1061-6.
7. Khorram O. DHEA: a hormone with multiple effects. Curr Opin Obstet Gynecol 1996;8:351-4
8. Young J, Couzinet B, Nahoul K, Brailly S, Chanson P, Baulieu EE, et al. Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. J Clin Endocrinol Metab 1997;82:2578-85.
9. Regelson W, Loria R, Kalimi M. Dehydroe-piandrosterone (DHEA) - the "mother steroid". I. Immunologie action. Ann NY Acad Sci 1994;719:553-63.
10. Suitters AJ, Shaw S, Wales MR, Porter JP, Leonard J, Woodger R, et al. Immune enhancing effects of dehydroepiandrosterone and dehydroepiandrosterone sulphate and the role of steroid sulphatase. Immunology 1997;91: 314-21.
11. Coleman DL, Leiter EA, Schwizer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 1982;31: 830.
12. Loria RM, Inge TH, Cook SS, Szakal AK, Regelson W. Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol 1988;26:301-14.
13. Hall GM, Perry LA, Spector TD. Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. Ann Rheum Dis 1993;52:211-4.
14. Wilder RL. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. J Rheumatol Suppl 1996;44: 10-2.
15. Luppa P, Munker R, Nagel D, Weber M, Engelhardt D. Serum androgens in intensivecare patients: correlations with clinical findings. Clin Endocrinol (Oxf) 1991;34:305-10.
16. Secreto G, Zumoff B. Abnormal production of androgens in women with breast cancer. Anticancer Res 1994;14:2113-7.
17. Legrain S, Berr C, Frenoy N, Gourlet V, Debuire B, Baulieu EE. Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology 1993;41:343-51.
18. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging, J Clin Endocrinol Metab 1997;82:2396-2402.
19. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984;59:551-5.
20. Sulcova J, Hill M, Hampl R, Starka L, Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulfate in normal subjects. J Endocrinol 1997; 154:57-62.
21. Manu P, Laine T, Matthews D. Chronic fatigue and chronic fatigue syndrome: clinical epidemiology and aetiological classification. In: Chronic fatigue syndrome. Ciba Foundation Symposium 173. London: John Wiley & Sons Ltd; 1993. p. 23-42.
22. Lahita RG. The connective tissue diseases and the overall influence of gender. Int J Fertil Menopausal Stud 1996;41:156-65.
23. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 1947;12:153-7.
24. Barrows DM Functional capacity evaluations of persons with chronic fatigue immune dysfunction syndrome. Am J Occup Ther 1995;49: 327-37.
25. Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine metabolic parameters in postmenopausal women. J Clin Endocrin Metab 1990;71:696-704.
26. Casson PR, Santoro N, Elkind-Hirsh K, Carson SA, Hornsby PJ, Abraham G, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-1 and decreases high density-lipoprotein: a six month trial. Fertil Steril 1998;70:107-10.